Kallyope Reports Successful Phase 2b Trial Outcomes for Elismetrep in Acute Migraine Treatment
Kallyope, a late-stage biotechnology company focused on neurological and metabolic therapies, announced positive results from its Phase 2b dose-ranging study of the lead candidate, elismetrep (K-304), for the acute treatment of migraine. This news is significant as elismetrep represents a potentially first-in-class oral therapy that leverages a novel mechanism of action, addressing a large population of patients who remain underserved by existing acute migraine treatments.
The drug operates as a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist. This target ...